Bli medlem
Bli medlem

Du är här

2016-11-03

Medical Prognosis Institute: MPI increases its capital with nominal DKK 2,000 as a result of exercise of 40,000 warrants

Hoersholm; November 3rd2016 - Medical Prognosis Institute A/S (MPI) announced
today that, as a consequence of an exercise of warrants in an ongoing warrant
program as described in the company description published June 21st 2016 the
share capital has been increased by nominal DKK 2,000.

The increase is affected without any pre-emption rights for the existing
shareholders of the company or others. The shares are subscribed in cash at a
price of DKK 0.52 per share of nominally DKK 0,05.

Proceeds to the company are DKK 20,800.

The new shares are ordinary shares without any special rights and are freely
transferable negotiable instruments. The new shares shall give rights to
dividends and other rights in relation to the company as of subscription,
i.e. inter alia full rights to dividends for the financial year 2016. MPI's
current share capital amounts to DKK 1,166,115 and will after the capital
increase be DKK 1,168,115. The capital increase is expected to be finalized
shortly.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)
MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to
predict which cancer patients are high likely to respond to a given
anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29
trials showed that drug-specific DRP(TM) Biomarkers could predict which
patients responded well to the treatment. The DRP(TM) platform has amongst
others been externally validated and published in collaboration with leading
statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be
used to design the Clinical Development Plan, i.e. to select which
indications are relevant for a given anti-cancer drug. In addition to
this, the individual genetic patterns of patients can be analyzed as part of
a screening procedure for a clinical trial to ensure inclusion of patients
with a high likelihood of response to the drug. DRP(TM) builds on comparison
between sensitive and resistant human cancer cell lines, including genomic
information from cell lines combined with clinical tumor biology and clinical
correlates in a systems biology network. The DRP(TM) is a Big Data tool based
on messenger RNA.
The DRP(TM) platform can be used in all cancer types, and has been patented
for more than 60 anti-cancer drugs in the US.

About MPI
Medical Prognosis is a publicly traded international company specialized in
improving cancer patients lives by developing Personalized Medicine using its
unique DRP(TM) technology. MPI's exceptional opportunity to personalize
cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma
and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its
ability to separate patients who benefit and who do not benefit from a
specific cancer treatment. This has been shown in as many as 29 out of 37
trials, and covers more than 80 anti-cancer treatments in a wide range of
cancer indications. MPI has built a significant large database with over
1,100 screened breast cancer patients and is building up a database in
Multiple Myeloma to be followed by Prostate cancer in collaboration with
oncologists and hematologists throughout Denmark.

For further information, please contact:
CEO, Peter Buhl Jensen, Adjunct Professor, MD, PhD
Ulla Hald Buhl, IR&Communication
E-mail: pbj@medical-prognosis.com
E-mail: uhb@medical-prognosis.com
Telephone: +45 21 60 89 22
Telephone +45 21 70 10 49

This information is information that Medical Prognosis Institute A/S is
obliged to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of the contact
person set out above, on November 3
rd
2016.

Certified Advisor:

Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden

Warrant exercise
http://hugin.info/158657/R/2054274/769050.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medical Prognosis Institute via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.